Literature DB >> 15958556

Secreted protein acidic and rich in cysteine produced by human melanoma cells modulates polymorphonuclear leukocyte recruitment and antitumor cytotoxic capacity.

Mariano J Alvarez1, Federico Prada, Edgardo Salvatierra, Alicia I Bravo, Viviana P Lutzky, Cecilia Carbone, Fernando J Pitossi, H Eduardo Chuluyan, Osvaldo L Podhajcer.   

Abstract

The expression of secreted protein acidic and rich in cysteine (SPARC) has been associated with the malignant progression of different types of human cancer. SPARC was associated with tumor cell capacity to migrate and invade, although its precise role in tumor progression is still elusive. In the present study, we show that SPARC produced by melanoma cells modulates the antitumor activity of polymorphonuclear leukocytes (PMN). Administration to nude mice of human melanoma cells in which SPARC expression was transiently or stably knocked down by antisense RNA (SPARC-sup cells) promoted PMN recruitment and obliterated tumor growth even when SPARC-sup cells accounted for only 10% of injected malignant cells. In addition, SPARC-sup cells stimulated the in vitro migration and triggered the antimelanoma cytotoxic capacity of human PMN, an effect that was reverted in the presence of SPARC purified from melanoma cells or by reexpressing SPARC in SPARC-sup cells. Leukotrienes, interleukin 8, and growth-related oncogene, in combination with Fas ligand and interleukin 1, mediated SPARC effects. These data indicate that SPARC plays an essential role in tumor evasion from immune surveillance through the inhibition of the antitumor PMN activity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15958556     DOI: 10.1158/0008-5472.CAN-04-1102

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  22 in total

1.  SPARC oppositely regulates inflammation and fibrosis in bleomycin-induced lung damage.

Authors:  Sabina Sangaletti; Claudio Tripodo; Barbara Cappetti; Patrizia Casalini; Claudia Chiodoni; Silvia Piconese; Alessandra Santangelo; Mariella Parenza; Ivano Arioli; Silvia Miotti; Mario P Colombo
Journal:  Am J Pathol       Date:  2011-10-11       Impact factor: 4.307

Review 2.  Anti-cancer role of SPARC, an inhibitor of adipogenesis.

Authors:  Ganji Purna Chandra Nagaraju; Dipali Sharma
Journal:  Cancer Treat Rev       Date:  2011-01-14       Impact factor: 12.111

Review 3.  Pathobiology of the neutrophil-intestinal epithelial cell interaction: role in carcinogenesis.

Authors:  Paul-M Hofman
Journal:  World J Gastroenterol       Date:  2010-12-14       Impact factor: 5.742

4.  Bone marrow-derived cathepsin K cleaves SPARC in bone metastasis.

Authors:  Izabela Podgorski; Bruce E Linebaugh; Jennifer E Koblinski; Deborah L Rudy; Mackenzie K Herroon; Mary B Olive; Bonnie F Sloane
Journal:  Am J Pathol       Date:  2009-08-21       Impact factor: 4.307

Review 5.  Positive and negative influence of the matrix architecture on antitumor immune surveillance.

Authors:  Elisa Peranzoni; Ana Rivas-Caicedo; Houcine Bougherara; Hélène Salmon; Emmanuel Donnadieu
Journal:  Cell Mol Life Sci       Date:  2013-05-07       Impact factor: 9.261

6.  Matricellular proteins: a sticky affair with cancers.

Authors:  Han Chung Chong; Chek Kun Tan; Royston-Luke Huang; Nguan Soon Tan
Journal:  J Oncol       Date:  2012-02-09       Impact factor: 4.375

7.  Protein profiling of human nonpigmented ciliary epithelium cell secretome: the differentiation factors characterization for retinal ganglion cell line.

Authors:  Ming-Hui Yang; Raghu R Krishnamoorthy; Shiang-Bin Jong; Pei-Yu Chu; Yuan-Han Yang; Wen-Cheng Chen; Sharon Chia-Ju Chen; Adnan Dibas; Thomas Yorio; Tze-Wen Chung; Yu-Chang Tyan
Journal:  J Biomed Biotechnol       Date:  2011-08-10

8.  SPARC: a matricellular regulator of tumorigenesis.

Authors:  Shanna A Arnold; Rolf A Brekken
Journal:  J Cell Commun Signal       Date:  2009-10-07       Impact factor: 5.782

9.  Tumour cell lines HT-29 and FaDu produce proinflammatory cytokines and activate neutrophils in vitro: possible applications for neutrophil-based antitumour treatment.

Authors:  Antonio Brú; Juan-Carlos Souto; Sonia Alcolea; Rosa Antón; Angel Remacha; Mercedes Camacho; Marta Soler; Isabel Brú; Amelia Porres; Luis Vila
Journal:  Mediators Inflamm       Date:  2010-02-11       Impact factor: 4.711

10.  The epithelial-mesenchymal transition (EMT) regulatory factor SLUG (SNAI2) is a downstream target of SPARC and AKT in promoting melanoma cell invasion.

Authors:  Nina Fenouille; Mélanie Tichet; Maeva Dufies; Anaïs Pottier; Ariane Mogha; Julia K Soo; Stéphane Rocchi; Aude Mallavialle; Marie-Dominique Galibert; Amir Khammari; Jean-Philippe Lacour; Robert Ballotti; Marcel Deckert; Sophie Tartare-Deckert
Journal:  PLoS One       Date:  2012-07-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.